Branford, Susan
,
Kim, Dennis Dong Hwan
Apperley, Jane F.
Eide, Christopher A.
Mustjoki, Satu http://orcid.org/0000-0002-0816-8241
Ong, S. Tiong
Nteliopoulos, Georgios
Ernst, Thomas
Chuah, Charles
Gambacorti-Passerini, Carlo http://orcid.org/0000-0001-6058-515X
Mauro, Michael J.
Druker, Brian J. http://orcid.org/0000-0001-8331-8206
Kim, Dong-Wook
Mahon, Francois-Xavier
Cortes, Jorge
Radich, Jerry P.
Hochhaus, Andreas
Hughes, Timothy P.
Article History
Received: 11 April 2019
Accepted: 23 April 2019
First Online: 17 June 2019
Compliance with ethical standards
:
: SB: Member of the advisory board of Qiagen, Novartis and Bristol-Myers Squibb; Received honoraria from Qiagen, Novartis, Bristol-Myers Squibb and Cepheid. Research support from Novartis. CC: Honorarium from Novartis Oncology, Bristol-Myers Squibb, Korea Otsuka Pharmaceuticals, Chiltern International; Research funding from Bristol-Myers Squibb. BJD: Aileron Therapeutics, ALLCRON, Cepheid, Vivid Biosciences, Celgene, Gilead Sciences (inactive), Baxalta (inactive), Monojul (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, Third Coast Therapeutics, GRAIL (inactive), CTI BioPharma (inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license). TPH: Holds a consultancy role and has received research funding and honoraria from Novartis, Bristol-Myers Squibb and Ariad. Other authors declare that they have no conflict of interest.